Delivery of large molecule drugs across the blood brain barrier is increasingly being seen as
an achievable goal. Several technologies have been described where following peripheral
administration the molecules can be detected in the brain. Foremost amongst these
technologies are antibodies against the transferrin receptor. Following a burst of
publications in the very early twenty first century, excitement seemed to wane as contrary
data started to emerge. Over the last few years antibodies against transferrin receptor have …